Hospital Sant Joan de Déu Barcelona
  • 2 lecturas

Guía metabólica

Hospital Sant Joan de Déu Barcelona

Traducir

Seguimiento de pacientes con síndrome de Hunter: registro del estudio de la evolución de Hunter (HOS)

Publicaciones científicas
26/09/2010

Introduction: Hunter syndrome, or mucopolysaccharidosis type II, is an inherited disease linked to the X chromosome that is caused by a deficit of the enzyme iduronate-2-sulfatase and its main symptoms affect the bones, neurological system and the viscera. In order to further our knowledge of its natural history, a registry containing data about patients' clinical histories was compiled. The purpose of this review is to describe how the registry works and to present the initial data concerning Spanish patients with Hunter syndrome included in it.

Development: The Hunter Outcome Survey (HOS) registry is a multi-centre, world-wide, observational, long-term follow-up study that is open to all patients diagnosed with the disease. The registry includes clinical data and information from the complementary examinations that are commonly performed as usual practice while attending these patients. Its main aims are to describe the population of patients with the disease, to further our knowledge of its natural history, to keep a check on the safety and effectiveness of enzyme replacement therapy in patients who are candidates for such treatment and to create a database that makes it possible to draw up a set of guidelines for clinical practice.

Conclusions: Specific registries of low-prevalence diseases, such as the HOS registry for patients with Hunter syndrome, are important to improve the follow-up of patients and to determine the impact of new treatments. The Spanish HOS registry is an important step forward in furthering our knowledge of the current situation of the patients registered throughout the country.

PMID: 17345554 [PubMed - indexed for MEDLINE]

[Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry][Article in Spanish] del Toro-Riera M. Rev Neurol 2007;44 Suppl 1:S13-7. Hospital Universitario Vall d'Hebron, 08035 Barcelona, Espana. mdeltoro@vhebron.net
Última modificación: 
27/09/2010
  • 239 lecturas

También te puede interesar

Publicaciones científicas

Mucoplisacaridosis tipo II (Síndrome de Hunter): revisión clínica y recomendaciones para el tratamiento en la era de la terapia de sustitución enzimática.

26/09/2010
Hasta hace poco no había terapia efectiva para la MPS II y los cuidados eran solo paliativos. Pero actualmente se ha introducido la terapia de sustitución enzimática (ERT) con iduronato-2-sulphatasa (idursulfasa) humana recombinante. Infusiones intravenosas semanales de...
Publicaciones científicas

Manejo multidisciplinario del síndrome de Hunter.

26/09/2010
El síndrome de Hunter es un trastorno minoritario, ligado al cromosoma X causado por la deficiencia de la enzima lisosomal iduronato-2-sulfatasa. En ausencia de suficiente actividad enzimática, los GAGs se acumulan en el lisosoma de muchos tejidos y órganos y contribuyen a la...
Publicaciones científicas

Estudio de pacientes y portadores con deficiencia de 2-metil-3-hidroxibutiril-CoA deshidrogenasa (MHBD): dificultad en el diagnóstico.

30/12/2011
Objetivos : Búsqueda de marcadores bioquímicos y moleculares para el diagnóstico de pacientes y portadores de la deficiencia de 2-metil-3-hidroxibutiril-CoA deshidrogenasa (MHBD). Diseño y métodos : Se analizaron los ácidos orgánicos en orina, la...